Status:
COMPLETED
Trial II of Lung Protection With Azithromycin in the Preterm Infant
Lead Sponsor:
Hubert Ballard
Collaborating Sponsors:
American Lung Association
Conditions:
Bronchopulmonary Dysplasia
Eligibility:
All Genders
Up to 72 years
Phase:
PHASE2
Brief Summary
The hypothesis of this study is that administration of azithromycin to ventilated premature infants will decrease the incidence and severity of BPD. The purpose of this study is to determine if Azith...
Detailed Description
The survival of preterm infants has increased dramatically and has been associated with an increase in BPD. The incidence of BPD among extremely low birthweight infants ranges from 45% to 90%. Develop...
Eligibility Criteria
Inclusion
- birthweight less than 1250 grams admitted to UK NICU
- mechanical ventilation within the first 72 hours of life
Exclusion
- confirmed sepsis by blood culture
- multiple congenital anomalies or known syndromes
- intrauterine growth retardation with birthweight less than 10%ile for gestational age
- ROM for \>7 days
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00319956
Start Date
September 1 2004
End Date
June 1 2012
Last Update
June 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky Medical Center
Lexington, Kentucky, United States, 40536